TY - JOUR
T1 - DNMT3A haploinsufficiency causes dichotomous DNA methylation defects at enhancers in mature human immune cells
AU - Lim, Jung Yeon
AU - Duttke, Sascha H.
AU - Baker, Turner S.
AU - Lee, Jihye
AU - Gambino, Kristyne J.
AU - Venturini, Nicholas J.
AU - Yuin Ho, Jessica Sook
AU - Zheng, Simin
AU - Fstkchyan, Yesai S.
AU - Pillai, Vinodh
AU - Fajgenbaum, David C.
AU - Marazzi, Ivan
AU - Benner, Christopher
AU - Byun, Minji
N1 - Funding Information:
This work was funded by Icahn School of Medicine at Mount Sinai, Castleman Disease Collaborative Network, Chan Zucker-berg Initiative Single-Cell Analysis of Inflammation Program, and National Institutes of Health (NIH) R01HL153974 to M. Byun; NIH K99GM135515 to S.H. Duttke; NIH U19AI135972 and GM134366 to C. Benner; the Burroughs Wellcome Fund, Chan Zuckerberg Initiative Neurodegeneration Challenge Network, Irma T. Hirschl Trust Young Investigator fellowship, and NIH U01AI150748 and R01AI143840 to I. Marazzi.
Funding Information:
Disclosures: D.C. Fajgenbaum reported grants from EUSA Pharma and non-financial support from Pfizer outside the submitted work; in addition, D.C. Fajgenbaum had a patent for "Methods of Treating Idiopathic Multicentric Castleman Disease with JAK1/2 inhibition" pending (no licensee) and a patent for "Treatment of Castleman Disease" pending (no licensee). No other disclosures were reported.
Publisher Copyright:
© 2021 Lim et al.
PY - 2021/5/10
Y1 - 2021/5/10
N2 - DNMT3A encodes an enzyme that carries out de novo DNA methylation, which is essential for the acquisition of cellular identity and specialized functions during cellular differentiation. DNMT3A is the most frequently mutated gene in age-related clonal hematopoiesis. As such, mature immune cells harboring DNMT3A mutations can be readily detected in elderly persons. Most DNMT3A mutations associated with clonal hematopoiesis are heterozygous and predicted to cause loss of function, indicating that haploinsufficiency is the predominant pathogenic mechanism. Yet, the impact of DNMT3A haploinsufficiency on the function of mature immune cells is poorly understood. Here, we demonstrate that DNMT3A haploinsufficiency impairs the gain of DNA methylation at decommissioned enhancers, while simultaneously and unexpectedly impairing DNA demethylation of newly activated enhancers in mature human myeloid cells. The DNA methylation defects alter the activity of affected enhancers, leading to abnormal gene expression and impaired immune response. These findings provide insights into the mechanism of immune dysfunction associated with clonal hematopoiesis and acquired DNMT3A mutations.
AB - DNMT3A encodes an enzyme that carries out de novo DNA methylation, which is essential for the acquisition of cellular identity and specialized functions during cellular differentiation. DNMT3A is the most frequently mutated gene in age-related clonal hematopoiesis. As such, mature immune cells harboring DNMT3A mutations can be readily detected in elderly persons. Most DNMT3A mutations associated with clonal hematopoiesis are heterozygous and predicted to cause loss of function, indicating that haploinsufficiency is the predominant pathogenic mechanism. Yet, the impact of DNMT3A haploinsufficiency on the function of mature immune cells is poorly understood. Here, we demonstrate that DNMT3A haploinsufficiency impairs the gain of DNA methylation at decommissioned enhancers, while simultaneously and unexpectedly impairing DNA demethylation of newly activated enhancers in mature human myeloid cells. The DNA methylation defects alter the activity of affected enhancers, leading to abnormal gene expression and impaired immune response. These findings provide insights into the mechanism of immune dysfunction associated with clonal hematopoiesis and acquired DNMT3A mutations.
UR - http://www.scopus.com/inward/record.url?scp=85105751794&partnerID=8YFLogxK
U2 - 10.1084/jem.20202733
DO - 10.1084/jem.20202733
M3 - Article
C2 - 33970190
AN - SCOPUS:85105751794
SN - 0022-1007
VL - 218
JO - Journal of Experimental Medicine
JF - Journal of Experimental Medicine
IS - 7
M1 - e20202733
ER -